TKI

DRUG13 trials

Sponsors

First People's Hospital of Hangzhou, Instituto Nacional de Cancerologia de Mexico, Institute of Cancer Research, United Kingdom, Tongji Hospital, Sun Yat-sen University

Conditions

Advanced HCCChemotherapyChronic Myelogenous LeukemiaChronic Myelogenous Leukemia - Chronic PhaseDriver MutationEGFR Gene MutationEfficacy and SafetyHepatocellular Carcinoma

Phase 2

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

First People's Hospital of HangzhouLung Adenocarcinoma

Start: 2016-05-31End: 2020-05-31Target: 46Updated: 2016-11-25

Stereotactic Body Radiotherapy for the Treatment of OPD

Institute of Cancer Research, United KingdomNSCLC

Start: 2017-11-27End: 2025-06-30Updated: 2023-12-26

Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer

CompletedNCT03595644

Tongji HospitalStage IV Non-small Cell Lung Cancer

Start: 2017-02-12End: 2020-12-10Updated: 2021-04-08

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

Yue HanUnresectable Hepatocellular Carcinoma

Start: 2021-11-05End: 2024-12-05Target: 48Updated: 2021-11-26

Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC

RecruitingNCT05277844

Tata Memorial HospitalDriver Mutation, Non-small Cell Lung Cancer, Oligometastatic Disease

Start: 2019-11-11End: 2027-11-11Target: 106Updated: 2025-09-10

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

RecruitingNCT06145308

Peking Union Medical CollegePrecision Therapy, Salivary Gland Carcinoma

Start: 2023-08-15End: 2028-07-10Target: 39Updated: 2026-04-02

Phase 3

Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2020-12-30End: 2022-12-01Target: 400Updated: 2021-01-13

TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

Not yet recruitingNCT07489755

Shenzhen TargetRx Co., Ltd.Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase

Start: 2026-04-01End: 2031-05-01Target: 180Updated: 2026-03-24

Unknown Phase

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

Instituto Nacional de Cancerologia de MexicoEGFR Gene Mutation, Non-Small Cell Adenocarcinoma, Tyrosine Kinase Mutation

Start: 2016-03-31End: 2017-12-31Target: 120Updated: 2017-03-07

A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML

RecruitingNCT05341050

xunaMMR on 12 Month

Start: 2022-04-01End: 2026-05-31Target: 260Updated: 2022-04-22

Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC

CompletedNCT06818097

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAdvanced HCC, Chemotherapy, Efficacy and Safety +3

Start: 2021-10-01End: 2025-04-01Updated: 2025-05-20

MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer

Not yet recruitingNCT06969781

Shanghai Chest HospitalLung Cancer (NSCLC)

Start: 2025-05-31End: 2028-12-31Target: 120Updated: 2025-05-14

CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC

CompletedNCT07449065

First Affiliated Hospital, Sun Yat-Sen UniversityHepatocellular Carcinoma (HCC), Microvascular Invasion (MVI), Transarterial Chemoembolization +1

Start: 2018-06-01End: 2025-10-31Updated: 2026-03-04

Related Papers

Anti-TROP2 ADC ESG401 in a master protocol clinical trial for salivary gland cancer based on molecular typing.

Journal of Clinical Oncology2025-05-28

Low BMI patients with advanced <i>EGFR</i> mutation-positive NSCLC can get a better outcome from metformin plus EGFR-TKI as first-line therapy: A secondary analysis of a phase 2 randomized clinical trial.

2023-06-171 citations

EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.

2023-04-2540 citations

Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.

Journal of Clinical Oncology2022-06-011 citations

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)

BMC Cancer2021-03-2320 citations

Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma

JAMA Oncology2019-09-05181 citations

Combination of metformin plus TKI vs. TKI alone in EGFR(+) LUNG adenocarcinoma: A randomized phase II study.

Journal of Clinical Oncology2018-05-209 citations